The professional listings in our magazine and on our website involve paid promotions, requiring advertisers to undergo a questionnaire demonstrating transparency.
While it’s a positive step that the DEA is allowing increased production of Vyvanse and its generic versions, the overall impact may be limited unless there are broader changes to the production caps. The ongoing prescription stimulant shortage remains a serious concern for patients who rely on these medications for conditions like ADHD and binge-eating disorder.
More comprehensive solutions are needed to ensure consistent access for those in need.
The professional listings in our magazine and on our website involve paid promotions, requiring advertisers to undergo a questionnaire demonstrating transparency.
1moWhile it’s a positive step that the DEA is allowing increased production of Vyvanse and its generic versions, the overall impact may be limited unless there are broader changes to the production caps. The ongoing prescription stimulant shortage remains a serious concern for patients who rely on these medications for conditions like ADHD and binge-eating disorder. More comprehensive solutions are needed to ensure consistent access for those in need.